Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chloro-phenylpiperazine in obsessive-compulsive disorder
1991; Elsevier BV; Volume: 36; Issue: 1 Linguagem: Inglês
10.1016/0165-1781(91)90113-4
ISSN1872-7123
AutoresEric Hollander, Concetta DeCaria, Robert Gully, Anca Nitescu, Raymond F. Suckow, Jack M. Gorman, Donald F. Klein, Michael R. Liebowitz,
Tópico(s)Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
ResumoTo investigate the effect of fluoxetine on serotonergic sensitivity in obsessive-compulsive disorder (OCD), the partial serotonin agonist metachlorophenylpiperazine (mCPP) was compared to placebo under double-blind conditions in six patients with OCD before and during treatment with fluoxetine. Readministration of oral mCPP (0.5 mg/kg) after at least 12 weeks of fluoxetine treatment did not increase obsessive-compulsive (OC) symptoms, in contrast to exacerbation of OC symptoms produced by mCPP before treatment. Chronic fluoxetine treatment resulted in a significant increase in prolactin and cortisol response to mCPP. This may be accounted for, however, by substantially increased plasma mCPP levels during fluoxetine treatment. Chronic fluoxetine treatment diminished the behavioral sensitivity to mCPP and did not diminish, but may have partially normalized, the neuroendocrine response to mCPP in patients with OCD. These adaptive homeostatic effects may reflect fluoxetine's antiobsessional mechanism.
Referência(s)